{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:12:43Z","timestamp":1777637563881,"version":"3.51.4"},"reference-count":87,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013365","name":"West China Hospital, Sichuan University","doi-asserted-by":"publisher","award":["2022HXFH034"],"award-info":[{"award-number":["2022HXFH034"]}],"id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To systematically evaluate the impact of pharmacist interventions on the implementation and clinical efficacy of vancomycin therapeutic drug monitoring (TDM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A Cochrane systematic review methodology was employed. Databases including PubMed, Medline, Embase, Cochrane Library, CNKI, and Sinomed were searched. After quality assessment and data extraction of eligible clinical studies, Meta-analysis was performed using Stata 18.0 to compare the differences between the pharmacist intervention group and the non-pharmacist intervention group in terms of the incidence of acute kidney injury, clinical effective rate, 30-day mortality, correct blood sampling time rate, target blood concentration attainment rate, TDM sampling rate, etc.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 63 studies were included in the Meta-analysis. The results showed that pharmacist interventions reduced the incidence of acute kidney injury (RR = 0.67, 95% CI = 0.57, 0.78, P &amp;lt; 0.05), improved the clinical effective rate (RR = 1.11, 95% CI = 1.06, 1.17, P &amp;lt; 0.05), reduced 30-day mortality (RR = 0.52, 95% CI = 0.33, 0.82, P &amp;lt; 0.05), increased the correct TDM blood sampling time rate (RR = 1.52, 95% CI = 1.25, 1.83, P &amp;lt; 0.05), increased the target blood concentration attainment rate (RR = 1.60, 95% CI = 1.49, 1.72, P &amp;lt; 0.05), increased the TDM sampling rate (RR = 1.65, 95% CI = 1.34, 2.04, P &amp;lt; 0.05), increased the proportion of dosage regimen adjustments based on TDM results (RR = 2.68, 95% CI = 1.93, 3.70, P &amp;lt; 0.05). There was no significant effect on the duration of medication, length of hospital stay or TDM timeliness. Subgroup analysis showed that In the 10\u201320\u00a0mg\/L group and the group with no specified target range, the serum concentration attainment rate was improved under pharmacist intervention (RR = 1.61, 95% CI = 1.50, 1.73, P &amp;lt; 0.05; RR = 1.49, 95% CI = 1.07, 2.08, P &amp;lt; 0.05). In the groups defined by serum creatinine increase \u22650.5\u00a0mg\/dL or \u226550% from baseline, and serum creatinine increase \u22650.3\u00a0mg\/dL or \u226550% from baseline, pharmacist interventions reduced the incidence of acute kidney injury (RR = 0.58, 95% CI = 0.45, 0.74, P &amp;lt; 0.05; RR = 0.64, 95% CI = 0.48, 0.85, P &amp;lt; 0.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study indicates that in patients treated with vancomycin under TDM, pharmacist interventions can promote the standardization of vancomycin TDM, reduce the incidence of acute kidney injury, and improve clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420261301721<\/jats:ext-link>\n                      , identifier CRD420261301721.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1805469","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T06:08:17Z","timestamp":1777442897000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of pharmacist intervention on therapeutic drug monitoring of vancomycin: a meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Mubai","family":"Ma","sequence":"first","affiliation":[{"name":"Department of Pharmacy, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongnan","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaqin","family":"Pan","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Chengdu Shangjin Nanfu Hospital","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guirong","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jsps.2012.01.002","article-title":"A survey of therapeutic drug monitoring services in Malaysia","volume":"21","author":"Ab Rahman","year":"2013","journal-title":"Saudi Pharmaceutical Journal"},{"key":"B2","doi-asserted-by":"publisher","first-page":"S337","DOI":"10.1093\/ofid\/ofz360.824","article-title":"756. Impact of infectious diseases pharmacists as part of an interdisciplinary OPAT team managing vancomycin","volume":"6","author":"Adamsick","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.jsps.2014.11.005","article-title":"Sampling time and indications appropriateness for therapeutically monitored drugs at a teaching university hospital in Oman","volume":"23","author":"Al Za Abi","year":"2015","journal-title":"Saudi Pharmaceutical Journal"},{"key":"B4","doi-asserted-by":"publisher","first-page":"A88","DOI":"10.26502\/acbr.50170116","article-title":"Impact of clinical pharmacist vancomycin monitoring on patient safety outcome","volume":"26","author":"Al-ruwaisan","year":"2019","journal-title":"Eur. J. Hosp. Pharm."},{"key":"B5","doi-asserted-by":"crossref","DOI":"10.26502\/acbr.50170116","article-title":"Impact of clinical pharmacist-vancomycin monitoring on patient safety outcome","volume-title":"Clinical and Biomedical Research 04","author":"Al-Ruwaisan","year":"2020"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e42952","DOI":"10.1097\/md.0000000000042952","article-title":"Therapeutic drug monitoring of vancomycin: a retrospective cross-sectional study of blood draw timing and clinical outcomes","volume":"104","author":"Alrasheed","year":"2025","journal-title":"Med. Baltim."},{"key":"B7","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jsps.2021.04.023","article-title":"Causes of vancomycin dosing error; problem detection and practical solutions; a retrospective, single-center, cross-sectional study","volume":"29","author":"Alzahrani","year":"2021","journal-title":"Saudi Pharm. J."},{"key":"B8","first-page":"e424","article-title":"Implementation of a pharmacy-directed vancomycin protocol in an acute care setting","volume":"55","author":"Brennan","year":"2015","journal-title":"J. Am. Pharm. Assoc."},{"key":"B9","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1186\/s40064-015-1146-9","article-title":"Optimization of time to initial vancomycin target trough improves clinical outcomes","volume":"4","author":"Cardile","year":"2015","journal-title":"Springerplus"},{"key":"B10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4212\/cjhp.3607","article-title":"The evaluation of a medical directive for pharmacist dosing of intravenous vancomycin","volume":"77","author":"Cesario","year":"2024","journal-title":"Can. J. Hosp. Pharm."},{"key":"B11","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1177\/0897190019826484","article-title":"Clinical and procedural evaluation of a pharmacy pharmacokinetic consult service","volume":"33","author":"Chanas","year":"2020","journal-title":"J. Pharm. Pract."},{"key":"B12","volume-title":"The analysis of the efficacy and safety of local application ofvancomycin in preventing infection after internal fixation of tibialplateau fracture and role of clinical pharmacist intervention inclinical rational application of patients. Master\u2019s thesis","author":"Chen","year":"2021"},{"key":"B13","volume-title":"The impact of pharmacist intervention on the clinical application of Vancomycin in pediatric patients in our hospital","author":"Chen","year":"2015"},{"key":"B14","first-page":"295","article-title":"Analysis of clinical administration behavior of vancomycin under clinical pharmacy intervention","volume":"15","author":"Chen","year":"2018","journal-title":"Chin. J. Drug Appl. Monit."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3000605221083242","DOI":"10.1177\/03000605221083242","article-title":"Therapeutic drug monitoring of vancomycin in neurosurgery patients, from trough concentration to area under the curve: a retrospective single center cohort study in a tertiary hospital","volume":"50","author":"Chen","year":"2022","journal-title":"J. Int. Med. Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.13286\/j.cnki.chinhosppharmacyj.2019.18.15","article-title":"Impact of Pharmacist-led antimicrobial stewardship program on appropriateness of antibiotic use in neonatal ICU","volume":"39","author":"Cheng","year":"2019","journal-title":"Chin. J. Hosp. Pharm."},{"key":"B17","doi-asserted-by":"publisher","first-page":"325","DOI":"10.7754\/clin.lab.2012.120425","article-title":"Evaluating appropriateness of digoxin, carbamazepine, valproic acid, and phenytoin usage by therapeutic drug monitoring","volume":"59","author":"Dalaklioglu","year":"2013","journal-title":"Clin. Lab."},{"key":"B18","article-title":"Study on optimizing vancomycin dosage regimens in patients with severe infections","volume-title":"2017 Chinese congress of clinical pharmacy and the 13th China clinical pharmacists forum","author":"Fang","year":"2017"},{"key":"B19","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/cpt.726","article-title":"The nephrotoxicity of vancomycin","volume":"102","author":"Filippone","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"B20","article-title":"Effect of clinical pharmacist intervention on serum vancomycin concentration monitoring in ICU patients","volume-title":"Journal of China Prescription drug. 20200315 ed","author":"Gao","year":"2019"},{"key":"B21","article-title":"Optimization of vancomycin individualized dosage regimens in patients with severe infections under the guidance of clinical pharmacists","volume-title":"Chinese journal of clinical rational drug use. 20241208 ed","author":"Gao","year":"2024"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e237","DOI":"10.1002\/j.1875-9114.2012.01219","article-title":"Improvement of vancomycin utilization in a community teaching hospital","volume":"32","author":"Gitman","year":"2012","journal-title":"Pharmacotherapy"},{"key":"B23","volume-title":"Study on individualized dosing strategy of vancomycinbased on SHIONOGI-VCM-TDM S1 and JPKD software. Master\u2019s thesis","author":"Han","year":"2022"},{"key":"B24","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1310\/hpj5204-273","article-title":"Impact of pharmacy practice model expansion on pharmacokinetic services: optimization of vancomycin dosing and improved patient safety","volume":"52","author":"Han","year":"2017","journal-title":"Hosp. Pharm."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1093\/ofid\/ofw172.1487","article-title":"Assessing the impact of a pharmacist-managed vancomycin protocol on the duration of empiric therapy","volume":"3","author":"Hanretty","year":"2016","journal-title":"Open Forum Infect. Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e134","DOI":"10.1002\/phar.2052","article-title":"Impact of a pharmacist-led vancomycin dosing and monitoring service at an academic medical center","volume":"37","author":"Harrison","year":"2017","journal-title":"Pharmacotherapy"},{"key":"B27","doi-asserted-by":"publisher","first-page":"S363","DOI":"10.1093\/cid\/ciaa1536","article-title":"Evidence-based guideline for therapeutic drug monitoring of vancomycin: 2020 update by the division of therapeutic drug monitoring, Chinese pharmacological society","volume":"71","author":"He","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2147\/IDR.S109485","article-title":"Pharmacist-managed dose adjustment feedback using therapeutic drug monitoring of vancomycin was useful for patients with methicillin-resistant Staphylococcus aureus infections: a single institution experience","volume":"9","author":"Hirano","year":"2016","journal-title":"Infect. and Drug Resist."},{"key":"B29","volume-title":"Clinical pharmacists' intervention using prescription automatic screening system in therapeutic drug monitoring","author":"Hu","year":"2012"},{"key":"B30","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1248\/yakushi.131.563","article-title":"Effect of pharmacists' intervention on the antibiotic therapy for the methicillin-resistant Staphylococcus aureus (MRSA) infectious diseases in the intensive care unit","volume":"131","author":"Imaura","year":"2011","journal-title":"Yakugaku Zasshi - J. Pharm. Soc. Jpn."},{"key":"B31","doi-asserted-by":"publisher","first-page":"169","DOI":"10.14163\/j.cnki.11-5547\/r.2020.28.076","article-title":"Analysis of the impact of pharmacist intervention on therapeutic drug monitoring of vancomycin in ICU patients","volume":"15","author":"Jiang","year":"2020","journal-title":"China Pract. Med."},{"key":"B32","volume-title":"Study on individualized pharmaceutical care for critically ill patients treated with vancomycin based on TDM. Master\u2019s thesis","author":"Jiang","year":"2022"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1111\/jcpt.13409","article-title":"Outcomes of a pharmacist-driven vancomycin monitoring initiative in a community hospital","volume":"46","author":"Joseph","year":"2021","journal-title":"J. Clin. Pharm. and Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"S98","DOI":"10.1093\/ofid\/ofy210.240","article-title":"The role of antimicrobial stewardship program on appropriate use, dose, and duration of vancomycin treatment","volume":"5","author":"Kaplun","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-021-00284-z","article-title":"Acute kidney injury","volume":"7","author":"Kellum","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e0203453","DOI":"10.1371\/journal.pone.0203453","article-title":"Effects of pharmacist intervention in vancomycin treatment for patients with bacteremia due to Methicillin-resistant Staphylococcus aureus","volume":"13","author":"Komoto","year":"2018","journal-title":"PLoS ONE"},{"key":"B37","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/maj.0000000000000368","article-title":"Pitfalls in dosing vancomycin","volume":"349","author":"Koppula","year":"2015","journal-title":"Am. J. Med. Sci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/bcp.15301","article-title":"Impact of pharmacist intervention in reducing vancomycin-associated acute kidney injury: a systematic review and meta-analysis","volume":"89","author":"Kunming","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B39","first-page":"47","article-title":"A multidisciplinary intervention improves vancomycin dosing in the intensive care unit","volume":"1","author":"Levin","year":"2010","journal-title":"J. Hosp. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"675","DOI":"10.4236\/ijcm.2016.710073","article-title":"Pharmacist and physician collaborative practice model improves vancomycin dosing in an intensive care unit","volume":"7","author":"Levin","year":"2016","journal-title":"Int. J. Clin. Med."},{"key":"B41","article-title":"Impact of the pharmacist intervention with a population pharmacokinetic model indevelopment of vancomycin dosage adjustment","volume-title":"2016 Chinese pharmaceutical congress and the 16th China pharmacist week","author":"Li","year":"2016"},{"key":"B42","doi-asserted-by":"publisher","first-page":"94","DOI":"10.12010\/j.issn.1673-5846.2022.12.021","article-title":"Analysis of the influencing factors of vancomycin plasma concentration and the influence of clinical pharmacists' intervention on the therapeutic effect","volume":"17","author":"Liao","year":"2022","journal-title":"China J. Pharm. Econ."},{"key":"B43","doi-asserted-by":"publisher","first-page":"619","DOI":"10.6039\/j.issn.1001-0408.2021.05.19","article-title":"Effects of integrated supervision mode by Doctors,Pharmacists and nurses on the Whole-processImplementation of TDM in our hospital","volume":"32","author":"Liu","year":"2021","journal-title":"China Pharm."},{"key":"B44","volume-title":"Study on optimization of vancomycin administration regimen based on population pharmacokinetics under the guidance of clinical pharmacists","author":"Lu","year":"2019"},{"key":"B45","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1080\/1120009X.2022.2086305","article-title":"Optimization of the vancomycin administration regimen by clinical pharmacists based on a population pharmacokinetics model: a prospective interventional study","volume":"34","author":"Lu","year":"2022","journal-title":"J. Chemother."},{"key":"B46","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/nep.13651","article-title":"Evaluation of interventions by pharmacists in vancomycin treatment in Chinese adult pneumonia patients: a randomized controlled trial","volume":"24","author":"Ma","year":"2019","journal-title":"Nephrology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1177\/1060028015587900","article-title":"Evaluation of a pharmacist-directed vancomycin dosing and monitoring pilot program at a tertiary academic medical center","volume":"49","author":"Marquis","year":"2015","journal-title":"Ann. Pharmacother."},{"key":"B48","doi-asserted-by":"publisher","first-page":"A242","DOI":"10.1136\/ejhpharm-2017-000640.541","article-title":"Evaluation of pharmacist intervention on vancomycin dosing and nephrotoxicity prevention","volume":"24","author":"Masoumi","year":"2017","journal-title":"Eur. J. Hosp. Pharm."},{"key":"B49","doi-asserted-by":"publisher","first-page":"284","DOI":"10.5414\/CP202274","article-title":"Impact of pharmacist intervention on preventing nephrotoxicity from vancomycin","volume":"53","author":"Masuda","year":"2015","journal-title":"Int. J. Clin. Pharmacol. and Ther."},{"key":"B50","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s10156-013-0599-4","article-title":"Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese society of chemotherapy and the Japanese society of therapeutic drug monitoring","volume":"19","author":"Matsumoto","year":"2013","journal-title":"J. Infect. Chemother."},{"key":"B51","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3390\/pharmaceutics14030489","article-title":"Clinical practice guidelines for therapeutic drug monitoring of vancomycin in the framework of model-informed precision dosing: a consensus review by the Japanese society of chemotherapy and the Japanese society of therapeutic drug monitoring","volume":"14","author":"Matsumoto","year":"2022","journal-title":"Pharmaceutics"},{"key":"B52","doi-asserted-by":"publisher","first-page":"02","DOI":"10.3390\/medicina58030370","article-title":"Experience of vancomycin therapeutic drug monitoring in two multidisciplinary hospitals in Latvia","volume":"58","author":"Maulina","year":"2022","journal-title":"Medicina"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1080\/0886022X.2016.1229992","article-title":"Evaluation of weight-based vancomycin dosing for hospitalized hemodialysis patients","volume":"38","author":"Maxson","year":"2016","journal-title":"Ren. Fail."},{"key":"B54","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1159\/000440607","article-title":"Safety and outcome of pharmacy-led vancomycin dosing and monitoring","volume":"61","author":"Momattin","year":"2015","journal-title":"Chemotherapy"},{"key":"B55","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1691\/ph.2018.8427","article-title":"Contribution of pharmacists with expertise in infectious diseases to appropriate individualized vancomycin dosing","volume":"73","author":"Nakashima","year":"2018","journal-title":"Pharmazie"},{"key":"B56","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1248\/bpb.b15-00774","article-title":"Clinical evaluation of pharmacist interventions in patients treated with anti-methicillin-resistant Staphylococcus aureus agents in a hematological ward","volume":"39","author":"Okada","year":"2016","journal-title":"Biol. Pharm. Bull."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1093\/ofid\/ofw172.1472","article-title":"Optimizing vancomycin prescribing through a pharmacist driven monitoring intervention at a children's hospital","volume":"3","author":"Olson","year":"2016","journal-title":"Open Forum Infect. Dis."},{"key":"B58","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"B59","volume-title":"Study on Influencing Factors of Valley concentration ofvancomycin and evaluation of intervention effect of clinical pharmacists","author":"Pan","year":"2021"},{"key":"B60","volume-title":"Effectiveness of a pharmacist managed vancomycin dosing protocol in achieving therapeutic levels in a Community Medical Center","author":"Patel","year":"2013"},{"key":"B61","article-title":"Effects of individualized dosing regimen on blood trough concentration of vancomycin and renal function in critically ill patients","volume-title":"China Pharmacy. 20231127 ed","author":"Peng","year":"2023"},{"key":"B62","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2146\/ajhp160760","article-title":"Novel approach to vancomycin level monitoring: impact of a multidisciplinary monitoring system on timing of vancomycin levels","volume":"75","author":"Peyko","year":"2018","journal-title":"Am. J. Health Syst. Pharm."},{"key":"B63","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2147\/IPRP.S92850","article-title":"Pharmacist-led implementation of a vancomycin guideline across medical and surgical units: impact on clinical behavior and therapeutic drug monitoring outcomes","volume":"4","author":"Phillips","year":"2015","journal-title":"Integr. Pharm. Res. and Pract."},{"key":"B64","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.ijantimicag.2012.11.010","article-title":"An educational intervention to improve vancomycin prescribing and monitoring","volume":"41","author":"Phillips","year":"2013","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B65","doi-asserted-by":"publisher","first-page":"e245","DOI":"10.1002\/phar.1877","article-title":"Effectiveness of a pharmacist to dose vancomycin consult service in attaining therapeutic trough levels in a teaching hospital","volume":"36","author":"Robinson","year":"2016","journal-title":"Pharmacotherapy"},{"key":"B66","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2146\/ajhp080434","article-title":"Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American society of health-system pharmacists, the infectious diseases society of America, and the society of infectious diseases pharmacists","volume":"66","author":"Rybak","year":"2009","journal-title":"Am. J. Health Syst. Pharm."},{"key":"B67","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American society of health-system pharmacists, the infectious diseases society of America, the pediatric infectious diseases society, and the society of infectious diseases pharmacists","volume":"77","author":"Rybak","year":"2020","journal-title":"Am. J. Health Syst. Pharm."},{"key":"B68","doi-asserted-by":"publisher","first-page":"A417","DOI":"10.1097\/01.ccm.0000365439.11849.a2","article-title":"Pharmacist managed vancomycin serum level monitoring leads to improved achievement of therapeutic target levels in children in pediatric intensive care unit (PICU)","volume":"37","author":"Shankar","year":"2009","journal-title":"Crit. Care Med."},{"key":"B69","volume-title":"Effect of clinical pharmacists intervention on Vancomycin use in cancer Hospital.","author":"Shao","year":"2019"},{"key":"B70","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/01.ccm.0000728624.59668.01","article-title":"Pharmacist-managed vancomycin therapy at a tertiary academic medical center","volume":"49","author":"Shuler","year":"2021","journal-title":"Crit. Care Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"505","DOI":"10.4140\/TCP.n.2016.505","article-title":"Impact of a pharmacist-initiated vancomycin monitoring program","volume":"31","author":"Smith","year":"2016","journal-title":"Consult Pharm."},{"key":"B72","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Bmj"},{"key":"B73","first-page":"298","article-title":"Evaluation of a pharmacist managed vancomycin therapy compared to physician managed dosing in establishing timely and therapeutic vancomycin serum concentrations at a community hospital","volume":"26","author":"Sussman","year":"2013","journal-title":"J. Pharm. Pract."},{"key":"B74","article-title":"Investigation of therapeutic drug monitoring of vancomycin by clinical pharmacists in neonates","volume-title":"Strait pharmaceutical journal","author":"Tao","year":"2020"},{"key":"B75","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1592\/phco.20.5.487.35054","article-title":"Practice guidelines for pharmacotherapy specialists","volume":"20","year":"2000","journal-title":"Pharmacotherapy"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1007\/s11096-021-01266-7","article-title":"Vancomycin dosing and therapeutic drug monitoring practices: guidelines versus real-life","volume":"43","author":"Van Der Heggen","year":"2021","journal-title":"Int. J. Clin. Pharm."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1177\/106002809402801201","article-title":"Impact of vancomycin therapeutic drug monitoring on patient care","volume":"28","author":"Welty","year":"1994","journal-title":"Ann. Pharmacother."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.2146\/ajhp160964","article-title":"Impact of a pharmacist-driven methicillin-resistant Staphylococcus aureus surveillance protocol","volume":"74","author":"Willis","year":"2017","journal-title":"Am. J. Health-System Pharm."},{"key":"B79","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/j.jval.2020.04.496","article-title":"Pin21 establish a pharmaceutical care mode for therapeutic drug monitoring of vancomycin and evaluate its effectiveness and economics","volume":"23","author":"Xiao","year":"2020","journal-title":"Value Health"},{"key":"B80","first-page":"499","article-title":"Establishment of a pharmaceutical care mode forTherapeutic drug monitoring of vancomycin andEvaluation of its effectiveness and economics","volume":"24","author":"Xiao","year":"2021","journal-title":"Front. Pharm. Sci."},{"key":"B81","article-title":"Research of optimal dosing regimens and therapeutic drug monitoring for vancomycin by clinical pharmacists:analysis of 7-year data","volume-title":"Chinese critical care medicine","author":"Xu","year":"2018"},{"key":"B82","doi-asserted-by":"publisher","first-page":"301","DOI":"10.11816\/cn.ni.2021-201357","article-title":"Impact of clinical pharmacist intervention ontherapeutic effect of vancomycin on patients withcentral nervous system infection","volume":"31","author":"Yang","year":"2021","journal-title":"Chin. J. Nosocomiology"},{"key":"B83","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1093\/jac\/dkw254","article-title":"Therapeutic drug monitoring of vancomycin: a guideline of the division of therapeutic drug monitoring, Chinese pharmacological society","volume":"71","author":"Ye","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"B84","doi-asserted-by":"publisher","first-page":"20420986251339580","DOI":"10.1177\/20420986251339580.(eng","article-title":"Pharmacist support in the entry of blood drug concentration test order avoids vancomycin-induced kidney injury","volume":"16","author":"Yoshikawa","year":"2025","journal-title":"Ther. Adv. Drug Saf."},{"key":"B85","volume-title":"Construction and application of vancomycin pharmaceutical service model","author":"Zhang","year":"2023"},{"key":"B86","doi-asserted-by":"publisher","first-page":"897","DOI":"10.14009\/j.issn.1672-2124.2019.08.001","article-title":"The expert consensus on the standards of therapeutic drug monitoring (2019 edition)","volume":"19","author":"Zhang","year":"2019","journal-title":"Eval. Analysis Drug-Use Hosp. China"},{"key":"B87","doi-asserted-by":"publisher","first-page":"427","DOI":"10.13664\/j.cnki.pcr.2014.05.045","article-title":"Technique and quality assurance of therapeutic drug monitoring","volume":"22","author":"Zhu","year":"2014","journal-title":"Pharm. Clin. Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1805469\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T06:08:30Z","timestamp":1777442910000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1805469\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":87,"alternative-id":["10.3389\/fphar.2026.1805469"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1805469","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"article-number":"1805469"}}